Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hematologic Malignancy Reports
Published in: Current Hematologic Malignancy Reports 4/2009

01-10-2009 | Clinical Trials Report

Chemoimmunotherapy with modified dosing of fludarabine, cyclophosphamide, and rituximab shows significant clinical activity in patients with previously untreated chronic lymphocytic leukemia

Authors: Nicole Lamanna, Mark A. Weiss

Published in: Current Hematologic Malignancy Reports | Issue 4/2009

Login to get access
Metadata
Title
Chemoimmunotherapy with modified dosing of fludarabine, cyclophosphamide, and rituximab shows significant clinical activity in patients with previously untreated chronic lymphocytic leukemia
Authors
Nicole Lamanna
Mark A. Weiss
Publication date
01-10-2009
Publisher
Current Science Inc.
Published in
Current Hematologic Malignancy Reports / Issue 4/2009
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-009-0034-1

Other articles of this Issue 4/2009

Current Hematologic Malignancy Reports 4/2009 Go to the issue

OriginalPaper

Update on the World Health Organization classification of peripheral T-cell lymphomas

Clinical Trials Report

Antilymphoma therapy with a Bcl-6 inhibitor

OriginalPaper

Vaccination strategies in follicular lymphoma

OriginalPaper

The host-tumor interface in B-cell non-Hodgkin lymphoma: A new world to investigate

OriginalPaper

Hemopoietic stem cell transplantation in T-cell malignancies: Who, when, and how?

OriginalPaper

Natural killer-cell neoplasms
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits